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order to avoid a graft-induced immune response. While simplifying the model, this has again 85 neglected a factor, which is critical when considering the transplantation of patients. To the 86 best of our knowledge, only one paper has thus far combined non-syngeneic VM transplants 87 and L-DOPA treatment (Soderstrom et al., 2008) . In that paper, L-DOPA was administered to 88 all groups with the focus being to explore the impact of inflammation on the synaptic 89 reorganization occurring the presence of L-DOPA. The study was however not designed to 90 compare the impact of L-DOPA treatment pre-and post-transplantation in a systematic 91
manner. 92 93
In determining the effect of L-DOPA on transplanted fetal dopaminergic precursors it is 94 therefore paramount to apply this technique in an improved simulation of 'real world' 95 conditions. The use of syngeneic tissue does not trigger a significant immune response in 96 rodents. Patients receive pooled allogeneic tissue from several donors and post-mortem 97 analysis performed on transplanted patients has illustrated that, even in well surviving grafts, 98 there are infiltrating B-and T-lymphocytes in the grafted putamen indicative of an 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 6 usually well tolerated in rats. Moreover, this would allow a full immunological response to be 125 observed, should the presence of L-DOPA have an impact. All animals were treated again 126 either with L-DOPA or saline for another 8 weeks following grafting (Figure 1, phase II: 127 daily for 4 weeks then every other day). Dyskinesias were assessed once a week during the 128 treatment phases I and II, both 'on' and 'off' L-DOPA (Scale B, as described in Breger and 129 colleagues (2013)). After 2 weeks to allow complete washout of the drug, motor test were 130 repeated. At the end of the experiment all animals were transcardially perfused with 1.5% 131 paraformaldehyde (Torres et al., 2006) . 132 b   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 selected based on the results of the amphetamine-induced rotation score. They were then 158 separated in 2 groups: 1) treated daily with L-DOPA and CSA (n=8), 2) treated daily with L-159 DOPA only (n=8). Abnormal involuntary movements (AIMs) were scored twice a week, for 160 4 weeks (L-DOPA 6mg/kg) and then once a week, for 2 weeks (L-DOPA 12mg/kg), 161 rotational behavior of the rats was recorded concomitantly. 162
Animals and materials 163
Sprague Dawley rats (experiment 1: n=122 and experiment 2: n=16; Harlan, UK) weighing 164 200-220g at the start of the experiment were housed 2-4 per cages with ad libitum access to 165 food and water. The experiments were approved by the Cardiff University AWERB and 166 pathway. Selective targeting of this site allows near total depletion of nigrostriatal 177 dopaminergic neurons as described by Torres and colleagues (2011) . Briefly, the rats were 178 anaesthetized with 2-3% Isoflurane (IVAK, UK) in a 2:1 O2/NO 2 mix and received an 179 infusion of 3 µl of a 30 mM solution of 6-OHDA.HBr (Sigma, UK) containing 0.03% acid 180 ascorbic into the right nigrostriatal pathway at the following coordinates AP -4.0 mm from 181 bregma; ML +1.3 mm from midline; DV -7.0mm below dura, with the nose-bar set at -182 4.5mm below the interaural line. The cannula remained in place for 3 min following 183 injection. Postoperatively, animals were sutured and received a 5 ml injection s.c. of 0.9% 184 sodium chloride containing 4% glucose for hydration and 10 μl of analgesic (5mg/ml 185 Meloxicam, Boehringer Ingleheim, Germany). Post-mortem analysis confirmed that all 186 animals had greater than 95% loss of tyrosine hydroxylase (TH) positive cells in the right 187 substantia nigra (no significant difference was observed between the different group F 11,106 = 188 1.01, p=0.4439, data not shown). 189
VM Transplant 190
According to a previous study, the optimal embryonic stage for mouse VM transplantation is 191 12 days post-copulatory (Torres et al., 2007) , corresponding to Carnegie stage 16, similarly 192 achieved at 14 days post-copulation in rats (Butler and Juurlink, 1987 After a wash in DNAse 0.1% in DMEM medium, VM were broken into small cells clusters 202 by mechanic dissociation using gentle pipette trituration. The solution was centrifuged at 203 2,000 rpm/min for 3 min and the number of cells was counted using a haemocytometer slide. 204
After centrifugation, the pellet was suspended in an adequate volume of DMEM 0.1% 205
DNAse to obtain a concentration of 100 000 cell/μl and loaded into a 10 μl Hamilton syringe. 206 2 μl of the cell suspension were injected over 2 min into the dopamine depleted striatum of 207 anaesthetized animals, at the following coordinates: AP: +0.5 mm; ML: -2.5 mm; DV: -5.0 208 mm and -4.0 mm (1 μl at each depth) with the nose-bar set at -4.5 mm allowing a flat head. 209
The syringe was left in place for an additional 3 min for diffusion before being retracted. 
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The rats were held in a way that allowed the forelimbs to move freely when the torso and 224 hind limbs were supported and moved upward from under the bench, allowing the whisker on 225 the tested side to gently brush the edge of the table. This should induce an automatic limb 226 placing response on the test side of an intact animal (Fleming and Schallert, 2011) . This test 227 was performed 10 times on each side in order to obtain a percentage estimate of response on 228 each side. At each time point (before lesion, after lesion and after grafting) the whole test was 229 repeated 3 times for each animal and the mean number of accurate placements across all tests 230 was calculated. 231
Stepping test 232
This task evaluates the ability of the rat to adjust a weight bearing forepaw in response to 233 movement along a flat surface. The rats were held above a flat bench allowing only one 234 forelimb to touch the surface of the table bearing weight (the body weight was largely 235 supported by the experimenter but some weight given to the paw). The rat was moved 236 laterally in both forehand and backhand directions across 1 meter of bench over a period of 237 10 s and the number of adjusting steps made by the paw was counted for each forelimb when 238 moved. This test was repeated 3 times at each time point (before lesion, after lesion, after 239 grafting). 240
Cylinder test 241
The rats were placed in a Perspex cylinder (height: 33.5 cm, diameter: 19 cm) and video 242 recorded. The cylinder was placed between two mirrors to allow scoring when the rats were 243 back to the camera. The number of forelimb touches made by each paw, out of the first 20 244 touches performed on the cylinder wall, was counted. Performance in the cylinder test was 245 used to assess the extent of the lesion and split the animals evenly amount the groups before 246 treatment and surgery. All of the above behavior tests were carried out by an experimenter 247 blind to the treatment of the animals. 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 at room temperature over night before being dehydrated and delipidated in a succession of 270 ethanol and xylene solutions. They were then cover-slipped with distyrene plasticizer and 271 xylene (DPX). The experimenter was blind to the experimental groups in assessment of the 272 histology. TH + cell bodies were counted on a Leica light microscope (20x) for all sections 273 12 from a 1 in 12 series through the rat striatum and the total number of dopaminergic cells was 274 estimated using the Abercrombie method (Hedreen, 1998) . TH+ fiber outgrowth was 275 measured by counting the number of intersection of fibers on a 10x10 square grid (each 276 square 500m 2 ; magnification: 20x) located immediately at the graft host border (periphery) 277 or in the center of the graft (center). Ox42 cells were counted within 3 frames (572 x 429 µm; 278 magnification: 20x), one placed in the middle of the graft and two at the transplant-host 279 border. Leukocyte counts were carried out using an automated stereology microscope 280 (Olympus BX50) and a PC-based image analysis software (Olympus C.A.S.T grid system 281 version 1.6). The whole striatum was outlined (4x) and the enclosed area was measured by 282 the software. Sections within the selected striatal area were sampled randomly and CD45+ 283 cells were counted within a regular series of 286 X 214 m window (40x). The total number 284 of cells was estimated using the following formula: N=   n x (A/a)  x F x T / (T+H) where 285 n=number of cells counted, A= inclusion area (striatum), a= total sampling area, F= 286 frequency of the sections (x12), T=thickness of the sections (40 m) and H=mean diameter 287 of the cells. The surface area of the blood vessel was estimated by taking pictures of the 288 sections, stained for Reca-1 (x10), on a Leica DMRBE microscope and analyzing them with 289
ImageJ software (version 1.45, National Institutes of Health, USA). The pictures were 290 converted in 8-bit black and white pictures and the threshold was adjusted to avoid 291 background noise, before the stained area was measured by the software and used as a 292 measure of blood vessel area. 293
Statistical analysis 294
Although the nature of dyskinesia rating data is ordinal, non-parametric tests do not permit 295 the analysis of interactions between the different key factors of experimental interest (Times, 296
Type of treatment, Immunological transplantation barriers) as is required for the factorial 297 design used in all experiments. Therefore, since 1) the categories of dyskinesia rating are 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13 strictly interval and monotonic 2) inspection of the data indicated that the scores were well 299 distributed between the different categories and 3) analysis of variance is recognized to be 300 extremely robust to derivation of the data from the normality of distribution, that is the basis 301 of the underlying mathematics (Box, 1953) , parametric two-and three-factor split plot 302
ANOVA was used for all analyses, with Newman-Keuls and Sidak's post hoc tests as 303 appropriate to determine the locus of specific significant effects. 304 Finally, the impact of a dopaminergic intra-striatal graft on motor function was assessed by 336 counting the number of lateralized steps and vibrissae-elicit limb placement performed on the 337 contralateral side to the lesion. No motor function recovery was observed in any of the 338 groups, regardless of the type graft or treatment that the rats received ( 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 16 None of the saline treated control group (SS, in each transplantation set) displayed rotational 354 behavior, beyond spontaneous ipsilateral rotations, which are commonly observed in 6-355 OHDA lesioned animals (Table 1, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 14.9 ± 4.6 9.8 ± 1.4 8.1 ± 0.9 3.0 ± 1.2 2.1 ± 1.2 11.00 ± 0.65 497.1 ± 96.03 LS 14.1 ± 3.7 9.1 ± 3.3 8.6 ± 1.9 9.1 ± 1.7 3.3 ± 1.5 1.4 ± 0.3 11.12 ± 1.65 432.96 ±195.70 LL 17.5 ± 4.9 14.5 ± 5.1 9.1 ± 1.6 5.5 ± 1.2 2.4 ± 0.6 1.9 ± 0.7 9.62 ± 1.85 470.7 ± 132.40
Results 305

L-DOPA treatment does not affect the survival or the function of the graft 306
Allograft SS 14.4 ± 2.9 15.4 ± 5.6 8.1 ± 0.9 9.3 ± 1.1 2.7 ± 0.4 2.6 ± 0.4 0.40 ± 0.40 -38.53 ± 17.95 SL 14.2 ± 2.5 13.8 ± 4.1 7.4 ± 0.6 7.6 ± 1.4 2.3 ± 0.8 1.5 ± 0.6 8.45 ± 1.89 126.9 ± 50.53 LS 16.8 ± 3.2 16.7 ± 6.9 8.7 ± 1.3 9.4 ± 1.1 2.5 ± 0.6 1.5 ± 0.3 7.91 ± 1.29 264.6 ± 111.6 LL 14.5 ± 2.9 21.7 ± 6.1 8.5 ± 1.0 8.6 ± 1.1 3.3 ± 0.6 2.8 ± 0.4 10.91 ± 1.51 251.9 ± 70.82
Xenograft SS 14.6 ± 3.2 26.2 ± 7.1 7.9 ± 1.1 6.2 ± 1.4 2.6 ± 0.5 1.7 ± 0.9 0.40 ± 0.27 -22.45 ± 6.78 
L-DOPA treatment influences immune response 404
Inflammation and immune response against the graft was evaluated using a microglia marker 405 (Ox42) and a leukocyte marker (CD45). The presence of the graft (regardless of type), 406 generally increased the number of microglia in the grafted area (Figure 4a-e, F 2 analyzed separately. In the SS group of rats that had never been exposed to L-DOPA, very 420 few CD45 + cells were observed (Figure 4g ). In contrast, in all groups that had been treated 421 with L-DOPA, a consistent increase in infiltrated cells was found throughout the striatum 422 (Figure 4h-j) . The mean number of leukocytes infiltrated in the 2 groups that received L-423 DOPA post-grafting was 3 and 6 times higher than in the SS control group (Figure 4f 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 2 ). Since no difference was found between the SS and LL groups in the 459 xenografted animals (considered to be the two most extreme scenarios), the other groups 460
were not analyzed (F 1,40 =0.105, p=0.748). 461 462
CSA does not interfere with AIMs development 463
In a separate experiment, L-DOPA (6 or 12mg/kg) was administered concomitantly with 464 CSA in order to assess potential interaction between the two treatments. As expected, both 465 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 (Kurowska et al., 2011) . All together, these data suggest that even 520 though dopaminergic grafts seem to survive quite well in presence of infiltrating immune 521 cells, at least for the first decade, they might eventually succumb to the host defense system. 522
It is noteworthy that in a recent analysis of a patient's brain 24 years after fetal transplant, 523 very good survival of the dopaminergic cells was found with limited immune response (as 524 assessed by IBA-1 and CD68 staining). Pertinent to this study, the patient did exceedingly 525 well post-transplantation such that his medication steadily reduced and benefited from a 526 complete withdrawal of L-DOPA two and half years after transplantation, while he remained 527 under immunosuppression for few years after that (Li et al., 2016) . 528
529
These observations of interactions between graft and drug treatment raise interesting clinical 530 and biological questions of critical relevance to the future development of non-autologous 531 cell transplantation for neurological conditions, and for the preclinical models that are used to 532 promote that translational goal. The mechanism by which chronic L-DOPA treatment ,1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Establishing a reliable animal model to study the parameters influencing the success of cell 560 therapy for PD is a crucial but convoluted task. To the best of our knowledge we are the first 561 group to attempt to replicate much of this multi factorial process. This has necessitated a 562 thorough and systematic approach, which has produced some insights into a possible 563 interaction between the graft, drug therapy and immune system. We have shown here that L-564 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
